Chean Dara, Luque-Paz David, Poole Daniele, Fodil Sofiane, Lengliné Etienne, Dupont Thibault, Kouatchet Achille, Darmon Michael, Azoulay Élie
Medical Intensive Care Unit, Saint-Louis Teaching Hospital, Paris University, 1 Avenue Claude Vellefaux, Paris, 75010, France.
European Society of Intensive Care Medicine (ESICM) Methodology Group, Anderlecht, Belgium.
Ann Intensive Care. 2025 Jan 16;15(1):9. doi: 10.1186/s13613-024-01409-9.
To describe the use of life-sustaining therapies and mortality in patients with acute leukemia admitted to the intensive care unit (ICU).
The PubMed database was searched from January 1st, 2000 to July 1st, 2023. All studies including adult critically ill patients with acute leukemia were included. Two reviewers independently selected the studies, assessed bias using the Newcastle-Ottawa scale for cohort studies, and performed data extraction from full-text reading. We performed a proportional meta-analysis using a random effects model. The primary outcome was all-cause ICU mortality. Secondary outcomes included reasons for ICU admission, use of organ support therapies (mechanical ventilation, vasopressors and renal replacement therapy), hospital, day-90 and one-year mortality rates.
Of the 1,331 studies screened, 136 (24,861 patients) met the inclusion criteria and were included in the meta-analysis. Acute myeloid leukemia affected 16,269 (66%) patients, acute lymphoblastic leukemia affected 835 (3%) patients, and the type of leukemia was not specified in 7,757 (31%) patients. Acute respiratory failure (70%) and acute circulatory failure (25%) were the main reasons for ICU admission. Invasive mechanical ventilation, vasopressors and renal replacement therapy, were needed in 65%, 53%, and 23% of the patients, respectively. ICU mortality was available in 51 studies (6,668 patients, of whom 2,956 died throughout their ICU stay), resulting in a metanalytical proportion of 52% (95% CI [47%; 57%]; I 93%). In a meta-regression, variables that influenced ICU mortality included year of publication, and intubation rate.
Acute respiratory failure is the main reason for ICU admission in patients with acute leukemia. Mechanical ventilation is the first life-sustaining therapy to be used, and also a strong predictor of mortality.
This study's protocol was preregistered on PROSPERO (CRD42023439630).
描述入住重症监护病房(ICU)的急性白血病患者生命维持治疗的使用情况及死亡率。
检索2000年1月1日至2023年7月1日的PubMed数据库。纳入所有包含成年急性白血病重症患者的研究。两名研究者独立选择研究,使用纽卡斯尔-渥太华量表评估队列研究的偏倚,并通过全文阅读进行数据提取。我们使用随机效应模型进行比例荟萃分析。主要结局是全因ICU死亡率。次要结局包括入住ICU的原因、器官支持治疗(机械通气、血管活性药物和肾脏替代治疗)的使用情况、住院死亡率、90天死亡率和1年死亡率。
在筛选的1331项研究中,136项(24861例患者)符合纳入标准并纳入荟萃分析。急性髓系白血病患者16269例(66%),急性淋巴细胞白血病患者835例(3%),7757例(31%)患者未明确白血病类型。急性呼吸衰竭(70%)和急性循环衰竭(25%)是入住ICU的主要原因。分别有65%、53%和23%的患者需要有创机械通气、血管活性药物和肾脏替代治疗。51项研究(6668例患者,其中2956例在ICU住院期间死亡)提供了ICU死亡率数据,荟萃分析比例为52%(95%CI[47%;57%];I²=93%)。在荟萃回归中,影响ICU死亡率的变量包括发表年份和插管率。
急性呼吸衰竭是急性白血病患者入住ICU的主要原因。机械通气是首先使用的生命维持治疗方法,也是死亡率的有力预测指标。
本研究方案已在PROSPERO上预先注册(CRD42023439630)。